Eli Lilly to Present Landmark monarchE Overall Survival Data for Verzenio in High-Risk Early Breast Cancer at 2025 ESMO Annual Meeting
I'm PortAI, I can summarize articles.
Eli Lilly and Company will present new data from its oncology portfolio at the 2025 ESMO Annual Meeting in Berlin, scheduled for October 17-21. Key presentations include the primary overall survival analysis from the Phase 3 monarchE study of Verzenio in high-risk early breast cancer, along with updated results from therapies targeting various cancers. These results have not yet been released.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments